Arkolith/Insider Trading/AMRX/Form 4

Boyer Andrew S

Executive Vice PresidentAmneal Pharmaceuticals, Inc. (AMRX) · full profile →Form 4 · filed Mar 5, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
15
10 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 4, 2026Option exercise(M)38K——445K
Mar 4, 2026Tax withholding(F)19K$13.30$255K426K
Mar 3, 2026Option exercise(M)398K——606K
Mar 3, 2026Tax withholding(F)12K$13.31$162K209K
Mar 3, 2026Option exercise(M)50K——221K
Mar 3, 2026Tax withholding(F)25K$13.31$331K197K
Mar 3, 2026Tax withholding(F)20K$13.31$265K172K
Mar 3, 2026Option exercise(M)39K——192K
Mar 3, 2026Option exercise(M)24K——221K
Mar 3, 2026Tax withholding(F)199K$13.31$2.7M407K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 4, 2026Option exercise(M)38K—$076K
Mar 3, 2026Option exercise(M)50K—$050K
Mar 3, 2026Option exercise(M)398K—$00
Mar 3, 2026Option exercise(M)39K—$00
Mar 3, 2026Option exercise(M)24K—$073K

Transaction Codes

M
Option exercise / conversion
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-015238) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML